XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Product, Geographic and Other Revenue Information
 3 Months Ended
Apr. 04, 2021
Segment Reporting [Abstract]  
Product, Geographic and Other Revenue Information Product, Geographic and Other Revenue Information
A. Geographic Information
The following summarizes revenues by geographic area:
 Three Months Ended
(MILLIONS)April 4,
2021		March 29,
2020		%
Change
United States$7,597 $5,289 44 
Developed Europe3,038 1,708 78 
Developed Rest of World1,123 919 22 
Emerging Markets2,824 2,166 30 
Revenues$14,582 $10,083 45 
We and our collaboration partner, BioNTech, have entered into agreements to supply pre-specified doses of BNT162b2 with multiple developed and emerging nations around the world and are continuing to deliver doses of BNT162b2 under such agreements. We currently sell the BNT162b2 vaccine directly to government and government sponsored customers. This includes supply agreements entered into in November 2020 and February 2021 with the European Commission (EC) on behalf of the different EU member states and certain other countries. Each EU member state submits its own BNT162b2 vaccine order to us and is responsible for payment pursuant to terms of the supply agreements negotiated by the EC.
B. Other Revenue Information
Significant Customers
For information on our significant wholesale customers, see Note 17B in our 2020 Form 10-K. Additionally, revenues from sales of BNT162b2 to the U.S. Government represented 14% of total revenues for the three months ended April 4, 2021. Accounts receivable from sales of BNT162b2 to the U.S. Government represented 12% of total trade accounts receivable as of April 4, 2021.
Significant Product Revenues
The following provides detailed revenue information for several of our major products:
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSApril 4,
2021		March 29,
2020
TOTAL REVENUES(a)
$14,582 $10,083 
Vaccines$4,894 $1,611 
BNT162b2 alliance revenues and direct sales
Active immunization to prevent COVID-19
3,462 — 
Prevnar 13/Prevenar 13Pneumococcal disease1,284 1,450 
FSME/IMMUN-TicoVacTick-borne encephalitis disease53 48 
NimenrixMeningococcal disease46 75 
All other VaccinesVarious49 38 
Oncology$2,862 $2,435 
IbranceHR-positive/HER2-negative metastatic breast cancer1,254 1,248 
Xtandi alliance revenuesmCRPC, nmCRPC, mCSPC267 209 
InlytaAdvanced RCC229 169 
SutentAdvanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor200 205 
XalkoriALK-positive and ROS1-positive advanced NSCLC134 149 
BosulifPhiladelphia chromosome–positive chronic myelogenous leukemia123 100 
Retacrit(b)
Anemia109 89 
Ruxience(b)
Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis
98 7 
Zirabev(b)
Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer
86 6 
Lorbrena
ALK-positive metastatic NSCLC
60 42 
AromasinPost-menopausal early and advanced breast cancer52 34 
BesponsaRelapsed or refractory B-cell acute lymphoblastic leukemia 50 44 
Braftovi
In combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy
47 37 
Mektovi
In combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation
35 37 
All other OncologyVarious119 59 
Internal Medicine$2,594 $2,332 
Eliquis alliance revenues and direct salesNonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism1,643 1,300 
Chantix/ChampixAn aid to smoking cessation treatment in adults 18 years of age or older217 270 
Premarin familySymptoms of menopause143 152 
PristiqDepression60 41 
ToviazOveractive bladder57 60 
All other Internal MedicineVarious474 509 
Hospital(a)
$2,343 $2,088 
SulperazonBacterial infections192 187 
MedrolAnti-inflammatory glucocorticoid99 129 
ZaviceftaBacterial infections94 49 
ZithromaxBacterial infections89 138 
VfendFungal infections80 74 
FragminTreatment/prevention of venous thromboembolism71 59 
EpiPenEpinephrine injection used in treatment of life-threatening allergic reactions66 84 
ZyvoxBacterial infections55 70 
PrecedexSedation agent in surgery or intensive care55 42 
IVIg Products(c)
Various105 98 
Pfizer CentreOne(d)
Various391 152 
All other Anti-infectivesVarious397 395 
All other HospitalVarious648 610 
Inflammation & Immunology (I&I)$1,065 $978 
Xeljanz
RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis
538 451 
Enbrel (Outside the U.S. and Canada)
RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis
319 347 
(MILLIONS)Three Months Ended
PRODUCTPRIMARY INDICATION OR CLASSApril 4,
2021		March 29,
2020
Inflectra/Remsima(b)
Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis
177 158 
All other I&IVarious31 22 
Rare Disease$824 $639 
Vyndaqel/VyndamaxATTR-cardiomyopathy and polyneuropathy453 231 
BeneFIXHemophilia B112 121 
Refacto AF/XynthaHemophilia A89 89 
GenotropinReplacement of human growth hormone80 103 
SomavertAcromegaly65 64 
All other Rare DiseaseVarious26 31 
Total Alliance revenues$1,770 $1,382 
Total Biosimilars(b)
$530 $288 
Total Sterile Injectable Pharmaceuticals(e)
$1,482 $1,401 
(a)On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See Note 1A. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.
(b)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Retacrit, Ruxience and Zirabev.
(c)Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.
(d)Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.
(e)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.
Deferred Revenues
Our deferred revenues primarily relate to advance payments received or receivable in connection with contracts that we entered into during 2021 and 2020 with various government or government sponsored customers in international markets for supply of BNT162b2. The deferred revenues associated with the advance payments related to BNT162b2 total $1.9 billion as of April 4, 2021 and $957 million as of December 31, 2020 and are recorded in current liabilities. The increase in the BNT162b2 deferred revenues during the first quarter of 2021 was the result of additional advance payments received as we entered into new or amended contracts or as we invoiced customers in advance of vaccine deliveries. During the first quarter of 2021, we recognized revenue of $192 million that was included in the balance of BNT162b2 deferred revenues as of December 31, 2020. The BNT162b2 deferred revenues as of April 4, 2021 will be recognized in Revenues proportionately as we deliver doses of the vaccine to our customers and satisfy our performance obligation under the contracts, which we expect to occur within the next 12 months.
Subsequent to the end of our fiscal first quarter of 2021 and through April 30, 2021, we received or were due additional advance payments associated with agreements to supply BNT162b2 totaling approximately $3.8 billion.